Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesDividends payablesLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Oramed Pharmaceuticals (ORMP) Total Non-Current Liabilities (2022 - 2025)

Oramed Pharmaceuticals (ORMP) has disclosed Total Non-Current Liabilities for 3 consecutive years, with $4.3 million as the latest value for Q3 2024.

  • For the quarter ending Q3 2024, Total Non-Current Liabilities fell 4.5% year-over-year to $4.3 million, compared with a TTM value of $4.3 million through Sep 2024, down 4.5%, and an annual FY2023 reading of $4.4 million, down 6.24% over the prior year.
  • Total Non-Current Liabilities was $4.3 million for Q3 2024 at Oramed Pharmaceuticals, down from $4.3 million in the prior quarter.
  • Across five years, Total Non-Current Liabilities topped out at $4.8 million in Q3 2022 and bottomed at $2.8 million in Q2 2022.
  • Average Total Non-Current Liabilities over 3 years is $4.3 million, with a median of $4.4 million recorded in 2023.
  • Peak annual rise in Total Non-Current Liabilities hit 61.92% in 2023, while the deepest fall reached 6.24% in 2023.
  • Year by year, Total Non-Current Liabilities stood at $4.7 million in 2022, then dropped by 6.24% to $4.4 million in 2023, then fell by 3.56% to $4.3 million in 2024.
  • Business Quant data shows Total Non-Current Liabilities for ORMP at $4.3 million in Q3 2024, $4.3 million in Q2 2024, and $4.4 million in Q1 2024.